Clinical Trial Update: Cetuximab, Cisplatin, and Irinotecan in Treating Patients With Metastatic Esophageal Cancer, Gastroesophageal Junction Cancer, or Gastric Cancer That Did Not Respond to Previous Irinotecan and Cisplatin [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated the combination of cetuximab, cisplatin, and irinotecan in patients with metastatic esophageal cancer, gastroesophageal junction ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Camptosar (irinotecan)
• ERBITUX (cetuximab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Esophageal Cancer, Gastric Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-11-25